New test drug may inhibit Alzheimer's protein
In a survey conducted by the research laboratory A new drug was discovered that could inhibit senile plaques in the brain that would lead to Alzheimer's. The results were published in the journal " Science Translational Medicine ."
The large accumulation of beta-amyloid protein is known to be one of the factors that lead to disease, creating plaques in the brain. The new drug, called verubecestat, works to reduce these plaques, acting directly on the enzyme BACE1, responsible for the appearance of beta-amyloid. Preliminary tests, performed with 32 patients, showed a reduction of up to 80% in levels of this protein. This is not the first time they have tried to create a drug with this function, but so far, all drugs created have had serious adverse effects on patients.
For the first time an oral BACE1 inhibitor drug has been authorized for a new phase involving many patients: about 3,500. Phase 3 of the research should be completed by July 2017 and, if the results remain satisfactory, the pill may be marketed within three years.
Symptoms are divided between typical and atypical. In the first group we included heartburn or heartburn (retrosternal burning) and regurgitation. In the second group we have feelings of food impaction, chronic cough, asthma, pulmonary fibrosis, pneumonia, chest pain, laryngitis, sinusitis, otitis, ulcers, hoarseness, hawking, halitosis and dental erosion.
A study published in the The Journal of Allergy and Clinical Immunology has revealed that prenatal exposure to pets, the type of birth of the mother, and ethnicity are factors that influence risks of developing allergies in children up to two years. The analysis was conducted by researchers from the Henry Ford Hospital in the United States.